Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy

American Journal of Kidney Diseases

Volumn 66, Issue 5, 2015, Pages 783-791

  Hogg, Ronald J ^a   Bay, R Curtis ^b   Jennette, J Charles ^c   Sibley, Richard ^d   Kumar, Sumit ^e   Fervenza, Fernando C ^f   Appel, Gerald ^g   Cattran, Daniel ^h   Fischer, Danny ⁱ   Hurley, R Morrison ^j   Cerda, Jorge ^k   Carter, Brad ^l   Jung, Beverly ^m   Hernandez, German ⁿ   Gipson, Debbie ^o   Wyatt, Robert J ^p  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b A T STILL UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Dallas Nephrology Associates   (United States)

^f MAYO CLINIC   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h TORONTO GENERAL HOSPITAL   (Canada)

ⁱ Kidney and Hypertension Center   (United States)

^j BC CHILDREN S HOSPITAL   (Canada)

^k Capital Dist Renal Physicians   (United States)

^l Kidney Specialists of Central Oklahoma   (United States)

^m ST PAUL S HOSPITAL   (Canada)

ⁿ TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^o UNIVERSITY OF MICHIGAN   (United States)

^p UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

IgA nephropathy (IgAN); MEST scores; Mycophenolate mofetil (MMF); proteinuria; randomized controlled trial (RCT); remission; urinary protein creatinine ratio (UPCR)

Indexed keywords

CREATININE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LISINOPRIL; LOSARTAN; MYCOPHENOLATE MOFETIL; OMEGA 3 ACID ETHYL ESTER; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; DRUG COMBINATION; ICOSAPENTAENOIC ACID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; CONTROLLED STUDY; CREATININE URINE LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNITED STATES; URINALYSIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG COMBINATION; GLOMERULONEPHRITIS, IGA; MIDDLE AGED; PATHOLOGY; PROTEINURIA; REMISSION; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; CREATININE; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LISINOPRIL; LOSARTAN; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTEINURIA; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945480407     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.06.013     Document Type: Article

References (33)

1. G. D'Amico The commonest glomerulonephritis in the world: IgA nephropathy Q J Med 64 245 1987 709 727
2. R.J. Wyatt, and R.J. Hogg Evidence-based assessment of treatment options for children with IgA nephropathies Pediatr Nephrol 16 2 2001 156 167
3. R.J. Wyatt, and B.A. Julian IgA nephropathy N Engl J Med 368 25 2013 2402 2414
4. J. Floege, and F. Eitner Current therapy for IgA nephropathy J Am Soc Nephrol 22 10 2011 1785 1794
5. D.C. Cattran, C. Greenwood, and S. Ritchie Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other anti-hypertensive agents and to patients receiving no therapy Am J Kidney Dis 23 2 1994 247 254
6. M. Praga, E. Gutiérrez, E. González, E. Morales, and E. Hernández Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial J Am Soc Nephrol 14 6 2003 1578 1583
7. R. Coppo, L. Peruzzi, A. Amore, and et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria J Am Soc Nephrol 18 6 2007 1880 1888
8. H.C. Park, Z.G. Xu, S. Choi, and et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy Nephrol Dial Transplant 18 6 2003 1115 1121
9. J.V. Donadio Jr., E.J. Bergstralh, K.P. Offord, D.C. Spencer, and K.E. Holley A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group N Engl J Med 331 18 1994 1194 1199
10. X. Chen, P. Chen, G. Cai, and et al. A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy Zhonghua Yi Xue Za Zhi 82 12 2002 796 801
11. S. Tang, J.C.K. Leung, L.Y.Y. Chan, and et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy Kidney Int 68 2 2005 802 812
12. S.C.W. Tang, A.W. Tang, S.S. Wong, J.C.K. Leung, Y.W. Ho, and K.N. Lai Long-term study of mycophenolate mofetil treatment in IgA nephropathy Kidney Int 77 6 2010 543 549
13. B.D. Maes, R. Oyen, K. Claes, and et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study Kidney Int 65 5 2004 1842 1849
14. G. Frisch, J. Lin, J. Rosenstock, and et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial Nephrol Dial Transplant 20 10 2005 2139 2145
15. A.C. Allison, S.J. Almquist, C.D. Muller, and E.M. Eugui In vitro immunosuppressive effects of mycophenolic acid and an ester pro drug, RS-61443 Transplant Proc 23 2 suppl 2 1991 10 14
16. R. Ziswiler, K. Steinmann-Niggli, A. Kappeler, C. Daniel, and H.P. Marti Mycophenolic acid: a novel approach to therapy of experimental mesangial proliferative glomerulonephritis J Am Soc Nephrol 9 11 1998 2055 2066
17. H.N. Reich, S. Troyanov, J.W. Scholey, and D.C. Cattran Toronto Glomerulonephritis Registry: remission of proteinuria improves prognosis in IgA nephropathy J Am Soc Nephrol 18 12 2007 3177 3183
18. D.C. Cattran, R. Coppo, H.T. Cook, and et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlation, and classification Kidney Int 76 5 2009 534 545
19. R. Coppo, S. Troyanov, R. Camilla, and et al. The Oxford IgA nephropathy clinicopathological classifications: as valid for children as for adults: Kidney Int 77 10 2010 921 927
20. R.J. Hogg, and R.J. Wyatt A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616] BMC Nephrol 5 2004 3
21. J. Cohen A coefficient of agreement for nominal scale Educat Psychol Measure 20 1960 37 46
22. G.J. Schwartz, G.B. Haycock, C.M. Edelmann Jr., and A. Spitzer A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine Pediatrics 58 2 1976 259 263
23. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1 1976 31 41
24. G. Xu, W. Tu, D. Jiang, and C. Xu Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis Am J Nephrol 29 5 2009 362 367
25. C.H.R. Tan, P.T. Loh, W.S. Yang, and C.M. Chan Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review Singapore Med J 49 10 2008 780 785
26. D. Roccatello, D. Rossi, F. Marletto, and et al. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression J Nephrol 25 2 2012 198 203
27. A.M. Herzenberg, A.B. Fogo, H.N. Reich, and et al. Validation of the Oxford classification of IgA nephropathy Kidney Int 80 3 2011 310 317
28. Y. Du, L. Hou, C. Zhao, M. Han, and Y. Wu Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil Pediatr Nephrol 27 5 2012 765 771
29. S. Edstöm Halling, M.P. Söderberg, and U.B. Berg Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification) Nephrol Dial Transplant 27 2 2012 715 722
30. S.H. Kang, S.R. Choi, H.S. Park, and et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy Nephrol Dial Transplant 27 1 2012 252 258
31. S. Troyanov, and F.C. Fervenza Validating the Oxford classification of IgA nephropathy Clin J Am Soc Nephrol 6 10 2011 2335 2336
32. R. Coppo, S. Troyanov, S. Bellur, and et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments Kidney Int 86 4 2014 828 836
33. Y.C. Kim, H.J. Chin, H.S. Koo, and S. Kin Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy PLoS One 8 8 2013 e71545